Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR von Oehler, V G, Qin, J, Ramakrishnan, R, Facer, G, Ananthnarayan, S, Cummings, C, Deininger, M, Shah, N, McCormick, F, Willis, S, Daridon, A, Unger, M, Radich, J P

Volltext

S877 SAFETY AND CLINICAL ACTIVITY OF AMV564, A CD33/CD3 T‐CELL ENGAGER, IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML): UPDATED RESULTS FROM THE PHASE 1 FIRST‐IN... von Westervelt, P., Roboz, G.J., Cortes, J.E., Altman, J.K., Oehler, V.G., Long, M., Kantarjian, H.M., Lee, S., Han, T.H., Guenot, J., Feldman, E.J., DiPersio, J.F.

Volltext

PF253 SAFETY AND RESOURCE UTILIZATION FOLLOWING EARLY HOSPITAL DISCHARGE AFTER INDUCTION CHEMOTHERAPY FOR ACUTE MYELOID LEUKEMIA (AML): A 4‐YEAR RETROSPECTIVE ANALYSIS von Howard, N.P., Halpern, A.B., Othus, M., Hendrie, P.C., Baclig, N.V., Buckley, S.A., Percival, M.‐E.M., Becker, P.S., Scott, B.L., Oehler, V.G., Gernsheimer, T.B., Keel, S.B., Orozco, J.J., Cassaday, R.D., Hartley, G.A., Welch, V., Estey, E.H., Walter, R.B.

Volltext